[ CAS No. 886593-45-9 ] {[proInfo.proName]}

Name: 886593-45-9|(4-(2-Hydroxypropan-2-yl)phenyl)boronic acid|97%
Brand: Ambeed
SKU: A515753
Price: 5.0 USD
Availability: InStock
Rating: 95 (30 reviews)

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

2D 3D

Structure of 886593-45-9 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 886593-45-9 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 886593-45-9 ]

SDS Specification

Alternatived Products of [ 886593-45-9 ]

Product Details of [ 886593-45-9 ]

CAS No. :	886593-45-9	MDL No. :	MFCD09992905
Formula :	C₉H₁₃BO₃	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	DPIDNFWCDMXMDY-UHFFFAOYSA-N
M.W :	180.01	Pubchem ID :	55267383
Synonyms :

Calculated chemistry of [ 886593-45-9 ]

Physicochemical Properties

Num. heavy atoms :	13
Num. arom. heavy atoms :	6
Fraction Csp3 :	0.33
Num. rotatable bonds :	2
Num. H-bond acceptors :	3.0
Num. H-bond donors :	3.0
Molar Refractivity :	51.89
TPSA :	60.69 Å²

Pharmacokinetics

GI absorption :	High
BBB permeant :	No
P-gp substrate :	No
CYP1A2 inhibitor :	No
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	Yes
Log Kp (skin permeation) :	-7.02 cm/s

Lipophilicity

Log Po/w (iLOGP) :	0.0
Log Po/w (XLOGP3) :	0.53
Log Po/w (WLOGP) :	-0.51
Log Po/w (MLOGP) :	0.38
Log Po/w (SILICOS-IT) :	-0.56
Consensus Log Po/w :	-0.03

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	1.0
Bioavailability Score :	0.55

Water Solubility

Log S (ESOL) :	-1.5
Solubility :	5.7 mg/ml ; 0.0317 mol/l
Class :	Very soluble
Log S (Ali) :	-1.38
Solubility :	7.58 mg/ml ; 0.0421 mol/l
Class :	Very soluble
Log S (SILICOS-IT) :	-1.53
Solubility :	5.25 mg/ml ; 0.0292 mol/l
Class :	Soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	1.0 alert
Leadlikeness :	1.0
Synthetic accessibility :	1.63

Safety of [ 886593-45-9 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P261-P305+P351+P338	UN#:	N/A
Hazard Statements:	H315-H319-H335	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 886593-45-9 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 886593-45-9 ]
Downstream synthetic route of [ 886593-45-9 ]

[ 886593-45-9 ] Synthesis Path-Upstream 1~2

1
[ 5419-55-6 ]
[ 2077-19-2 ]
[ 886593-45-9 ]

Yield	Reaction Conditions	Operation in experiment
13%	Stage #1: With n-butyllithium In tetrahydrofuran; hexanes at -78℃; for 3.5 h; Stage #2: at 20℃; for 72 h;	PREPARATION 33; 2-(4-phenylboronic acid)propan-2-ol. n-BuLi (2.5 M in hexanes, 1.00 mL, 2.5 mmol) was added to a -78°C solution of PP51 (0.50 g, 2.33 mmol) in THF (20 mL). After 1.5 hrs, an additional 0.95 mL n-BuLi (2.38 mmol) was added and the mixture was stirred for 2 additional hrs. Triisopropyl borate (1.08 mL, 4.66 mmol) was added and the reaction was warmed to rt and stirred for 3 days. 1 N HCI was added and the mixture was extracted 3x with EtOAc. The extracts were washed with brine, dried (MgSO₄) and concentrated to give 0.29 g of crude product. Chromatography, first flushing with 50percent EtOAc/ hexanes and then eluting with 10percent MeOH/EtOAc, gave partially EPO <DP n="77"/>pure material which was then triturated with ether to yield 51 mg (13percent) of PP33 as a white solid: NMR (MeOH-d4) 7.67 (d, J = 8.3 Hz, 1 H), 7.54 (d, J = 7.88 Hz, 1 H), 7.45-7.40 (m, 2H), 1.97 (s, 6H).

Reference： [1] Patent: WO2006/48727, 2006, A1, . Location in patent: Page/Page column 75-76

2
[ 676-58-4 ]
[ 149104-90-5 ]
[ 886593-45-9 ]

Reference： [1] Patent: WO2009/70873, 2009, A1, . Location in patent: Page/Page column 70-71

[ 886593-45-9 ] Synthesis Path-Downstream 1~31

1
[ 886593-36-8 ]
[ 886593-45-9 ]
1-[4-(1-hydroxy-1-methyl-ethyl)-phenyl]-3-(2-[2-(4-methyl-piperazin-1-yl)-phenyl]-ethyl)-1,3-dihydro-benzoimidazol-2-one [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
22%	With triethylamine;copper diacetate; In dichloromethane; at 20℃; for 96h;	EXAMPLE 12; EPO <DP n="51"/>1-r4-(1-Hvdroxy-1-methylethyl)phenv?-3-{2-r2-(4-methyl-piperazin-1-v?phenyllethyl\|-1 ,3-dihvdrobenzoimidazol-2-one;.PP27 (0.052 g, 0.155 mmol), PP33 (0.05Og, 0.305 mmol), triethylamine (0.065 ml_,0.466 mmol) and copper (ll)acetate (0.056 g, 0.4308 mmol) in CH2CI2 (2mL) were stirred for 4 days at rt. The mixture was concentrated, EtOAc and aq. K2CO3 were added and the mixture was stirred vigorously for 90 min, then filtered (Celite) to remove insoluble copper salts. The organic phase was washed with brine, dried (MgSO4) and concentrated to yield 16 mg (22%) of Example 12 as a light tan oil. The maleate salt had: mp ~120-140C (amorphous); NMR(MeOH-d4) 7.66 (d, J = 8.7 Hz, 2H), 7.36 (d, J= 8.3 Hz, 2H), 7.24-7.00 (m, 8H), 6.23 (s, 2H), 4.24 (t, J = 7.3 Hz, 2H), 3.48-3.42 (m, 2H), 7.24-7.00 (m, 8H), 6.23 (s, 2H), 4.24 (t, J= 7.3 Hz,2H), 3.48-3.42 (m, 2H), 3.32-3.20 (m, 2H), 3.15-3.11 (m, 4H), 3.07-2.98 (m, 2H), 2.89 (s, 3H),1.55 (s, 6H).

Reference： [1]Patent: WO2006/48727,2006,A1 .Location in patent: Page/Page column 49-50

2
[ 676-58-4 ]
[ 149104-90-5 ]
[ 886593-45-9 ]

Yield	Reaction Conditions	Operation in experiment
		To a suspension of 4-acetylbenzeneboronic acid (5 g, 5 mmol) in diethyl ether at0 0C was added 2M methylmagnesium chloride (60 mL, 180 mmol). The mixture was stirred at RT for 30 min and quenched with the addition of 3N HCl. The product was extracted with EA and the organic layer was dried as usual. After removal of the solvent, the residue was subjected to chromatography on S1O2 using acetone:toluene:acetic acid (30:70:1) as eluant to give the boronic acid used in Step 2 without further purification. IH NMR (500 MHz, acetone-d): delta 7.8(2H, d), 7.5 (2H, d), 1.5 (6H, s) ppm.

Reference： [1]Patent: WO2009/70873,2009,A1 .Location in patent: Page/Page column 70-71

3
[ 5419-55-6 ]
[ 2077-19-2 ]
[ 886593-45-9 ]

Yield	Reaction Conditions	Operation in experiment
13%		PREPARATION 33; 2-(4-phenylboronic acid)propan-2-ol. n-BuLi (2.5 M in hexanes, 1.00 mL, 2.5 mmol) was added to a -78C solution of PP51 (0.50 g, 2.33 mmol) in THF (20 mL). After 1.5 hrs, an additional 0.95 mL n-BuLi (2.38 mmol) was added and the mixture was stirred for 2 additional hrs. Triisopropyl borate (1.08 mL, 4.66 mmol) was added and the reaction was warmed to rt and stirred for 3 days. 1 N HCI was added and the mixture was extracted 3x with EtOAc. The extracts were washed with brine, dried (MgSO4) and concentrated to give 0.29 g of crude product. Chromatography, first flushing with 50% EtOAc/ hexanes and then eluting with 10% MeOH/EtOAc, gave partially EPO <DP n="77"/>pure material which was then triturated with ether to yield 51 mg (13%) of PP33 as a white solid: NMR (MeOH-d4) 7.67 (d, J = 8.3 Hz, 1 H), 7.54 (d, J = 7.88 Hz, 1 H), 7.45-7.40 (m, 2H), 1.97 (s, 6H).

Reference： [1]Patent: WO2006/48727,2006,A1 .Location in patent: Page/Page column 75-76

4
[ 886593-45-9 ]
C₁₅H₁₇IN₄O₂S [ No CAS ]
[ 1093872-21-9 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2014,vol. 24,p. 1968 - 1973

5
[ 886593-45-9 ]
[ 1093877-97-4 ]
C₂₂H₂₂N₂O₄S [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2014,vol. 24,p. 1968 - 1973

6
[ 886593-45-9 ]
3,5-dimethoxyphenyl 2,3,4,5,6-pentafluorobenzenesulfonate [ No CAS ]
2-(3',5'-dimethoxy[1,1'-biphenyl]-4-yl)propan-2-ol [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
95%	With bis-triphenylphosphine-palladium(II) chloride; potassium phosphate monohydrate; In tert-butyl alcohol; at 28℃; for 12h;Schlenk technique; Inert atmosphere; Sealed tube;	General procedure: Procedure A: To a Schlenk tube equipped with a magnetic stiring bar and a teflon septum was charged K3PO4.H2O (1.5 mmol, 3 equiv), aryl pentafluorobenzene sulfonate (0.5 mmol, 1.0 equiv), aryl boronic acid (0.75 mmol, 1.5 equiv) and Pd(PPh3)2Cl2 (0.015 mmol, 3 mol%). The tube was then capped with a rubber septum, evacuated and backfilled with nitrogen and this cycle was repeated twice. Under an inertatmosphere, tert - butanol (3 mL) was added via syringe. Under a positive pressure of nitrogen, the rubber septum was replaced with a Teflon screw cap and this was sealed. The Schlenk tube was stirred at room temperature for the time indicated. When the reaction was completed according to TLC or GCMS (FID), thereaction mixture was diluted with EtOAc (5 mL) and filtered through celite bed. The organic layer was concentrated under reduced pressure. The residue was purified through silica gel (230 - 400 mesh) column chromatography using 1-10% ethyl acetate in petroleum ether to afford the product.

Reference： [1]Tetrahedron Letters,2015,vol. 56,p. 5106 - 5111

7
[ 876343-09-8 ]
[ 886593-45-9 ]
C₂₁H₁₈ClN₃O₃S [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With tetrakis(triphenylphosphine) palladium(0); sodium carbonate; In 1,2-dimethoxyethane; water; at 110℃; for 2h;	To a solution of 4-chloro-6-iodo-7-(phenylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidine (550 mgs, 1.31 mmol) and <strong>[886593-45-9](4-(2-hydroxypropan-2-yl)phenyl)boronic acid</strong> (286 mgs, 1.21 mmol) in DME (5 mL), was added 2.0 M aq Na2C03 (1.7 mL, 3.28 mmol) and Pd(PPh3)4 (75 mgs, 0.066 mmol) and the reaction mixture was heated at 1 10 C for 2 hr. The mixture was then diluted with water and acetonitrile and the resulting solid was filtered and washed with ether and dried to give 2-(4-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-6- yl)phenyl)propan-2-ol which was used further without purification. LCMS-ESI+ (m/z): [M+H]+ calcd for C2iH18CIN303S: 428.9; found: 428.2

Reference： [1]Patent: WO2015/187684,2015,A1 .Location in patent: Page/Page column 177

8
[ 886593-45-9 ]
5-(6-(4-(2-hydroxypropan-2-yl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-2-((tetrahydro-2H-pyran-4-yl)oxy)benzonitrile [ No CAS ]

Reference： [1]Patent: WO2015/187684,2015,A1

9
[ 886593-45-9 ]
5-(6-(4-(2-hydroxypropan-2-yl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-2-(morpholinomethyl)benzonitrile [ No CAS ]

Reference： [1]Patent: WO2015/187684,2015,A1

10
[ 886593-45-9 ]
C₃₃H₃₀N₄O₅S [ No CAS ]

Reference： [1]Patent: WO2015/187684,2015,A1

11
[ 886593-45-9 ]
C₃₃H₃₁N₅O₄S [ No CAS ]

Reference： [1]Patent: WO2015/187684,2015,A1

12
[ 886593-45-9 ]
N-[6-bromo-5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-[tetrahydropyran-4-yl-(2,2,2-trifluoroacetyl)amino]benzamide [ No CAS ]
N-[5-[(3,5-difluorophenyl)methyl]-6-[4-(1-hydroxy-1-methylethyl)phenyl]-1H-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(tetrahydropyran-4-ylamino)benzamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
24%	With (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; caesium carbonate; In 1,4-dioxane; at 120℃; for 1h;Inert atmosphere; Sealed tube;	To a mixture of N- [6-bromo-5 -[(3 ,5-difluorophenyl)methyl] -1 H-indazo 1-3 -yl] -4-(4-methylpiperazin- l-yl)-2- [tetrahydropyran-4-yl-(2 ,2,2-trifluoroacetyl)amino]benzamide(130 mg, 0.18 mmol), boronic acid (140 mg, 0.45 mmol), Cs2CO3 (1M, 0.50 ml) in dioxane(2.5 ml) was added Pd(dppf)C12 (30 mg) under argon atmosphere. The mixture was heatedto 120C in a sealed tube and stirred for 60 minutes. The solvent was removed and theresidue was purified by flash column chromatography with a gradient eluent from DCM:MeOH 100:1 to 40:1 and preparative HPLC to afford the title compound as white solid (30 mg, 24 %).1H NMR (400 MHz, DMSO-d6) oe 12.68 (s, 1H), 10.18 (s, 1H), 8.35-8.33 (m, 1H),7.81 (d, J= 9.2 Hz, 1H), 7.54 (s, 1H), 7.51 (s, 1H), 7.49 (s, 1H), 7.23 (s, 1H), 7.19 (s, 1H),7.17 (s, 1H), 6.92-6.87 (m, 1H), 6.44-6.42 (m, 2H), 6.24 (dd, J= 8.0 Hz, 1.9 Hz, 1H), 6.13(d, J= 2.0 Hz, 1H), 5.06 (s, 1H), 4.00 (s, 2H), 3.83-3.79 (m, 2H), 3.70-3.66 (m, 1H), 3.52-3.46 (m, 2H), 3.27-3.23 (m, 4H), 2.44-2.43 (m, 4H), 2.22 (s, 3H), 1.95-1.92 (m, 2H), 1.47(s, 6H), 1.38-1.29 (m, 2H).(ESI+) MS: m/z 695.3 (MHj.

Reference： [1]Patent: WO2016/96709,2016,A1 .Location in patent: Page/Page column 92; 93

13
[ 886593-45-9 ]
2-bromo-8-(2-(trifluoromethyl)phenyl)-7,8-dihydro-6H-pyrrolo [2',1:2,3]imidazo[4,5-b]pyridin-6-ol [ No CAS ]
2-(4-(2-hydroxypropan-2-yl)phenyl)-8-(2-(trifluoromethyl)phenyl)-7,8-dihydro-6H-pyrrolo[2’,1‘:2,3]imidazo[4,5-b]pyridin-6-ol [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With potassium phosphate; dichloro[1,1?-bis[bis(1,1-dimethylethyl)phosphino]ferrocene-P,P?]palladium; In 1,4-dioxane; at 90℃; for 2h;Sealed tube;	General procedure: A suspension of Intermediate 1G, 2-bromo-8-(2-(trifluoromethyl)phenyl)-7,8- dihydro-6H-pyrrolo[2,1:2,3]imidazo[4,5-b]pyridin-6-ol (30.0 mg, 75 mumol) and (4-(2- hydroxypropan-2-yl)phenyl)boronic acid (16.3 mg, 90 mumol) in dioxane (753 mul) and tripotassium phosphate (2.0 M aq solution) (113 mul, 226 mumol) was degassed for several minutes with N2. While still degassing, 1,1-bis(di-tert-butylphosphino)ferrocene palladium dichloride (1.825 mg, 2.80 mumol) mmol) was added. The vial was sealed and heating at 90 C for 1 h, at which point the reaction was analyzed by LCMS and judged incomplete. Additional boronic acid (7.0 mg, 0.52 eq), was added at room temperature, the reaction mixture was degassed, and additional 1,1-bis(di-tert-butylphosphino) ferrocene palladium dichloride (1.8 mg, 2.80 mumol) was added. The vial was sealed, and heated at 90 C with stirring for an additional 1 h. At this point the reaction was analyzed by LCMS and judged complete (m/z 454.1, M+H for desired product). The reaction mixture was allowed to cool to room temperature, the volatiles removed under reduced pressure and the reaction mixture was diluted with methanol at room temperature and filtered through a 13 mm syringe filter with a 0.45 mu Nylon membrane. The filtrate was purified via preparative LC/MS with the following conditions: Column: XBridge C18, 19 × 200 mm, 5-mum particles; Mobile Phase A: 5:95 acetonitrile:water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile:water with 10-mM ammonium acetate; Gradient: 20-60% B over 19 minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the desired product were combined and dried via centrifugal evaporation. Yield: 25 mg as a mixture of four enantiomers

Reference： [1]Patent: WO2016/149436,2016,A1 .Location in patent: Page/Page column 52;53

14
[ 886593-45-9 ]
2-bromo-6-fluoro-8-(2-(trifluoromethyl)phenyl)-7,8-dihydro-6H-pyrrolo[2',1':2,3]imidazo[4,5-b]pyridine [ No CAS ]
2-(4-(6-fluoro-8-(2-(trifluoromethyl)phenyl)-7,8-dihydro-6H-pyrrolo[2',1':2,3]imidazo[4,5-b]pyridin-2-yl)phenyl)propan-2-ol [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With potassium phosphate; dichloro[1,1?-bis[bis(1,1-dimethylethyl)phosphino]ferrocene-P,P?]palladium; In 1,4-dioxane; at 90℃; for 1.16667h;Inert atmosphere; Sealed tube;	A stirred solution of Intermediate 14A, 2-bromo-6-fluoro-8-(2-(trifluoromethyl) phenyl)-7,8-dihydro-6H-pyrrolo[2,1:2,3]imidazo[4,5-b]pyridine (45 mg, 0.112 mmol) and <strong>[886593-45-9](4-(2-hydroxypropan-2-yl)phenyl)boronic acid</strong> (26 mg, 0.146 mmol) in dioxane (1.1 mL) and tripotassium phosphate (2.0 M aq solution) (169 mul, 0.337 mmol) was degassed for several minutes with N2. While still degassing, 1,1-bis(di-tert-butylphosphino) ferrocene palladium dichloride (7.30 mg, 0.0112 mmol) mmol) was added. The vial was sealed and heating at 90 C for 70 minutes, at which point the reaction mixture was analyzed by LCMS and judged complete (m/z 456.0, M+H for desired product).

Reference： [1]Patent: WO2016/149436,2016,A1 .Location in patent: Page/Page column 56-58

15
[ 886593-45-9 ]
2-bromo-8-(2-(trifluoromethyl)phenyl)-7,8-dihydro-6H-pyrrolo [2',1':2,3]imidazo[4,5-b]pyridine [ No CAS ]
2-(4-(8-(2-(trifluoromethyl)phenyl)-7,8-dihydro-6H-pyrrolo[2',1':2,3]imidazo[4,5-b]pyridin-2-yl)phenyl)propan-2-ol [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With potassium phosphate; dichloro[1,1?-bis[bis(1,1-dimethylethyl)phosphino]ferrocene-P,P?]palladium; In 1,4-dioxane; at 90℃; for 1.66667h;Sealed tube;	A solution of Intermediate 25B (2-bromo-8-(2-(trifluoromethyl)phenyl)-7,8- dihydro-6H-pyrrolo[2,1:2,3]imidazo[4,5-b]pyridine) (35.0 mg, 92 mumol) and (4-(2- hydroxypropan-2-yl)phenyl)boronic acid (19.8 mg, 110 mumol) in dioxane (1 mL) and tripotassium phosphate (2.0 M aq solution) (140 mul, 275 mumol) was degassed for several minutes with N2. While still degassing, 1,1-bis(di-tert-butylphosphino)ferrocene palladium dichloride (1.8 mg, 2.80 mumol) mmol) was added. The vial was sealed and heated at 90 C with stirring for 70 minutes. The reaction mixture was analyzed by LCMS analysis at this point and judged to be incomplete. Additional boronic acid (9.0 mg, 0.54 eq) was added at room temperature, the reaction mixture was degassed, and additional 1,1-bis(di-tert-butylphosphino)ferrocene palladium dichloride (1.8 mg, 2.80 mumol) was added, the vial was sealed, and heating at 90 C with stirring was carried out for 30 minutes, at which point at which point the reaction was analyzed by LCMS and judged to be complete (m/z 438.3, M+H for desired product). Yield of individual enantiomers (absolute stereochemistry undetermined): (0359) 7.5 mg (9.93%), 99% pure, enantiomer 1. 1H NMR (500 MHz, DMSO-d6) d 8.03 (d, J=8.3 Hz, 1H), 7.86 (d, J=7.2 Hz, 1H), 7.74 (d, J=8.2 Hz, 3H), 7.59-7.50 (m, 2H), 7.45 (d, J=8.2 Hz, 2H), 6.99 (d, J=7.4 Hz, 1H), 6.00 (br. s., 1H), 5.07 (s, 1H), 3.32-3.21 (m, 2H), 3.20-3.07 (m, 1H), 2.48-2.41 (m, 1H), 1.40 (s, 6H). (0360) 8.3 mg (7.05%), 93% pure, enantiomer 2. 1H NMR (500 MHz, DMSO-d6) d 8.03 (d, J=8.3 Hz, 1H), 7.86 (d, J=7.2 Hz, 1H), 7.74 (d, J=8.2 Hz, 3H), 7.59-7.50 (m, 2H), 7.45 (d, J=8.2 Hz, 2H), 6.99 (d, J=7.4 Hz, 1H), 6.00 (br. s., 1H), 5.07 (s, 1H), 3.32-3.21 (m, 2H), 3.20-3.07 (m, 1H), 2.48-2.41 (m, 1H), 1.40 (s, 6H).

Reference： [1]Patent: WO2016/149436,2016,A1 .Location in patent: Page/Page column 61;63;64

16
[ 886593-45-9 ]
trans-2-chloro-9-(2-(difluoromethoxy)phenyl)-6,9-dihydro-7H-pyrano[4',3':4,5]imidazo[1,2-b]pyridazin-6-ol [ No CAS ]
rac-(6S,9S)-9-(2-(difluoromethoxy)phenyl)-2-(4-(2-hydroxypropan-2-yl)phenyl)-7,9-dihydro-6H-pyrano[4',3':4,5]imidazo[1,2-b]pyridazin-6-ol [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
34%	With potassium phosphate; dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II)*CH2Cl2; In water; N,N-dimethyl-formamide; at 90℃; for 2h;Inert atmosphere; Sealed tube;	A mixture of fra ,-2-chloro-9-(2-(difluoromethoxy)phenyl)-7,9-dihydro-6H- pyrano[4',3':4,5]imidazo[l,2-b]pyridazin-6-ol (6 mg, 0.016 mmol), (4-(2-hydroxypropan- 2-yl)phenyl)boronic acid (3.52 mg, 0.020 mmol), PdCl2(dppf)-CH2Cl2 adduct (2.66 mg, 3.26 muiotatauiotaomicron) and 2.0 M aqueous potassium phosphate (0.016 mL, 0.033 mmol) in N,N- dimethylformamide (0.8 mL) was degassed with nitrogen in a sealed vial and heated to 90 C for 2 h. The mixture was cooled to room temperature and purified via preparative LC/MS with the following conditions: Column: Waters XBridge CI 8, 19 chi 200 mm, 5- muiotatauiota particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95 :5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 25- 100% B over 20 minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the product were combined and dried via centrifugal evaporation to give rac- (6S,9S)-9-(2-(difluoromethoxy)phenyl)-2-(4-(2-hydroxypropan-2-yl)phenyl)-7,9- dihydro-6H-pyrano[4',3':4,5]imidazo[l ,2-b]pyridazin-6-ol (2.6 mg, 34% yield). LC/MS (M+l): 468.1 ; HPLC RT=1.48 min (analytical HPLC Method A). NMR (500 MHz, DMSO-de) delta 8.18 (d, J=9.6 Hz, 1H), 7.76 (d, J=9.7 Hz, 1H), 7.64 (d, J=8.2 Hz, 2H), 7.55-7.42 (m, 3H), 7.42-7.20 (m, 2H), 7.20-7.10 (m, 1H), 6.93 (d, J=7.3 Hz, 1H), 6.44 (s, 1H), 4.87 (d, J=4.6 Hz, 1H), 4.1 1-3.98 (m, 1H), 3.73 (dd, J=l 1.9, 5.2 Hz, 1H), 1.41 (s, 6H).

Reference： [1]Patent: WO2016/149437,2016,A1 .Location in patent: Page/Page column 75-76

17
[ 886593-45-9 ]
2-chloro-9-(2-(difluoromethoxy)phenyl)-7,9-dihydro-6H-pyrano [4',3':4,5]imidazo[1,2-b]pyridazine [ No CAS ]
2-(4-(9-(2-(difluoromethoxy)phenyl)-7,9-dihydro-6H-pyrano[4',3':4,5]imidazo[1,2-b]pyridazin-2-yl)phenyl)propan-2-ol [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
90%	With potassium phosphate; dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II)*CH2Cl2; In water; N,N-dimethyl-formamide; at 90℃; for 2h;Inert atmosphere; Sealed tube;	A mixture of 2-chloro-9-(2-(difluoromethoxy)phenyl)-7,9-dihydro-6H-pyrano [4',3':4,5]imidazo[l,2-b]pyridazine (10 mg, 0.028 mmol), (4-(2-hydroxypropan-2-yl) phenyl)boronic acid (6.14 mg, 0.034 mmol), PdCl2(dppf)-CH2Cl2 adduct (4.64 mg, 5.69 muiotatauiotaomicron) and 2.0 M aqueous potassium phosphate (0.028 mL, 0.057 mmol) in N,N- dimethylformamide (0.8 mL) was degassed with nitrogen in a sealed vial and heated to 90 C for 2 h. The mixture was cooled to room temperature and purified via preparative LC/MS with the following conditions: Column: Waters XBridge CI 8, 19 chi 200 mm, 5- muiotatauiota particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95 :5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 25- 100% B over 20 minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the desired product were combined and dried via centrifugal evaporation to give 2-(4-(9-(2-(difluoromethoxy)phenyl)-7,9-dihydro-6H-pyrano[4',3':4,5]imidazo[l ,2- b]pyridazin-2-yl)phenyl)propan-2-ol (1 1.8 mg, 90% yield). LC/MS (M+1): 452.0; HPLC RT=1.60 min (analytical HPLC Method B). NMR (500 MHz, DMSO-de) delta 8.1 1 (d, J=9.5 Hz, 1H), 7.71 (d, J=9.4 Hz, 1H), 7.62 (d, J=8.1 Hz, 2H), 7.55-7.41 (m, 3H), 7.41 - 7.22 (m, 2H), 7.22-7.06 (m, 2H), 6.40 (s, 1H), 4.18 (d, J=l l . l Hz, 1H), 4.00 (m, 1H), 3.1 1 (d, J=16.6 Hz, 1H), 3.01 -2.81 (m, 1H), 1.42 (s, 6H).

Reference： [1]Patent: WO2016/149437,2016,A1 .Location in patent: Page/Page column 83-84

18
[ 886593-45-9 ]
(+/-)-cis-2-chloro-9-(2-(difluoromethoxy)phenyl)-6,7,8,9-tetrahydropyrido-[4',3':4,5]imidazo[1,2-b]pyridazin-6-ol [ No CAS ]
(+/-)-cis-9-(2-(difluoromethoxy)phenyl)-2-(4-(2-hydroxypropan-2-yl)phenyl)-6,7,8,9-tetrahydropyrido[4',3':4,5]imidazo[1,2-b]pyridazin-6-ol [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium phosphate; In 1,4-dioxane; water; at 105℃; for 2h;Inert atmosphere; Sealed tube;	A reaction vial was charged with (+/-)-cw-6-((teri-butyldiphenylsilyl)oxy)-2- chloro-9-(2-(difluoro-methoxy)phenyl)-6,7,8,9 etrahydropyrido[4',3':4,5]imidazo[l,2-b] pyridazine (10 mg, 0.027 mmol), <strong>[886593-45-9](4-(2-hydroxypropan-2-yl)phenyl)boronic acid</strong> (6.38 mg, 0.035 mmol), 2M aqueous solution of potassium phosphate tribasic (0.041 mL, 0.082 mmol) and dioxane (0.3 mL). The resulting mixture was deoxygenated by bubbling nitrogen through the mixture for ~ 5 min, then PdCl2(dppf) (0.998 mg, 1.363 muetaiotaomicron) was added, the vial was capped, and the mixture was heated at 105 C for 2 h. The reaction mixture was cooled, diluted with MeOH, filtered through a Millipore (0.45 muiotatauiota) filter and was further purified via preparative LC/MS with the following conditions: Column: XBridge CI 8, 19 chi 200 mm, 5-mupiiota particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 10-50% B over 20 minutes, then a 5-minute hold at 100% B; Flow: 20 mL/rnin to afford after concentration of fractions containing the product (+/-)-cz ,-9-(2-(difluoromethoxy)phenyl)-2-(4-(2-hydroxypropan-2-yl)phenyl)-6,7,8,9- tetrahydropyrido[4',3':4,5]imidazo[l ,2-b]pyridazin-6-ol. NMR (500MHz, DMSO-de): delta 8.09 (d, J=9.6 Hz, 1H), 7.69 (d, J=9.6 Hz, 1H), 7.57 (d, J=8.2 Hz, 2H), 7.46 (d, J=8.3 Hz, 2H), 7.41-7.34 (m, 1H), 7.34-7.29 (m, 1H), 7.22 (br. s., 1H), 7.14-7.06 (m, 1H), 7.02 (d, J=7.5 Hz, 1H), 5.61 (s, 1H), 4.71 (br. s., 1H), 3.18-3.04 (m, 1H), 2.99 (dd, J=14.2, 4.8 Hz, 1H), 1.39 (s, 6H). LC retention time 1.41 min (Method E). LC/MS (M+H): 467.

Reference： [1]Patent: WO2016/149437,2016,A1 .Location in patent: Page/Page column 63

19
[ 886593-45-9 ]
(+/-)-cis-2-chloro-9-(2-(difluoromethoxy)phenyl)-6,7,8,9-tetrahydropyrido-[4',3':4,5]imidazo[1,2-b]pyridazin-6-ol [ No CAS ]
(6R,9R)-9-(2-(difluoromethoxy)phenyl)-2-(4-(2-hydroxypropan-2-yl)phenyl)-6,7,8,9-tetrahydropyrido[4',3':4,5]imidazo[1,2-b]pyridazin-6-ol [ No CAS ]
(6S,9S)-9-(2-(difluoromethoxy)phenyl)-2-(4-(2-hydroxypropan-2-yl)phenyl)-6,7,8,9-tetrahydropyrido[4',3':4,5]imidazo[1,2-b]pyridazin-6-ol [ No CAS ]

Reference： [1]Patent: WO2016/149437,2016,A1

20
[ 886593-45-9 ]
(±)-6-bromo-3-chloro-N-(1-(2-fluorophenyl)ethyl)-2-methylquinolin-4-amine [ No CAS ]
(±)-2-(4-(3-chloro-4-((1-(2-fluorophenyl)ethyl)amino)-2-methylquinolin-6-yl)phenyl)propan-2-ol [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
48%	With dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II)*CH2Cl2; In water; N,N-dimethyl-formamide; at 90℃; for 2h;Inert atmosphere; Sealed tube;	A mixture of 6-bromo-3 -chloro-N-( 1 -(2-fluorophenyl)ethyl)-2-methylquinolin-4-amine (10 mg, 0.025 mmol, Intermediate 1-59), <strong>[886593-45-9](4-(2-hydroxypropan-2-yl)phenyl)boronic acid</strong> (5.49 mg, 0.030 mmol)), PdC12(dppf)-CH2C12 adduct (4.15 mg, 5.08 tmol)and 2.0 M aqueous potassium phosphate (0.025 mL, 0.051 mmol) in N,N10 dimethylformamide (0.5 mL) was degassed with nitrogen in a sealed vial and heated to 90C for 2 h. The mixture was cooled to room temperature and purified via preparative LC/MS using the following conditions: Column: Waters XBridge C18, 19 x 200 mm, 5-lim particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate;Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 25-100% B over 20 minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min. Fractionscontaining the desired product were combined and dried via centrifugal evaporation togive Example 308 (5.5 mg, 48% yield). LC/MS (M+H): 449.1; LC retention time: 2.26mm (analytical HPLC Method A); ?H NMR (500 IVIFIz, DMSO-d6) oe 8.24 (s, 1H), 7.96(d, J8.6 Hz, 1H), 7.86 (d, J8.8 Hz, 1H), 7.72 (t, J=7.3 Hz, 1H), 7.55 (m, 4H), 7.38-7.25

Reference： [1]Patent: WO2017/23905,2017,A1 .Location in patent: Page/Page column 273; 274

21
[ 886593-45-9 ]
[ 726169-75-1 ]
C₃₅H₄₆BNO₃ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With tetrakis(triphenylphosphine) palladium(0); caesium carbonate; In 1,4-dioxane; water; at 80℃; for 6h;Inert atmosphere;	(3) Take the product obtained in step (1) 500mg,Add 20 ml of 1,4-dioxane solution and4mL water mixture,One equivalent of 4- (2-hydroxy-2-propyl) phenylboronic acid was added,10% equivalent of tetrakis (triphenylphosphine) palladium,3 equivalents of cesium carbonate at 80 under argon,After 6 hours of reaction, the product (TM-2) was obtained by column chromatography.

Reference： [1]Patent: CN107445885,2017,A .Location in patent: Paragraph 0150; 0153

22
[ 886593-45-9 ]
5-bromo-3-[4-(propan-2-yloxy)phenyl]-3H-imidazo[4,5-b]pyridine [ No CAS ]
2-(4-{3-[4-(propan-2-yloxy)phenyl]-3H-imidazo[4,5-b]pyridin-5-yl}phenyl)propan-2-ol [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
47%	With [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II); potassium carbonate; In 1,2-dimethoxyethane; water; at 90℃; for 5h;Inert atmosphere;	To a solution of 5-bromo-3-[4-(propan-2-yloxy)phenyl]-3H-imidazo[4,5-b]pyrid me (ii mg, 0.033 mmol) in 1 ,2-dimethoxyethane (0.4 mL) were added <strong>[886593-45-9][4-(2-hydroxypropan-2-yl)phenyl]boronic acid</strong> (12 mg,0.066 mmol), [i,i?-bis(diphenylphosphino)ferrocene]palladium(ll) dichloride (2.4 mg, 0.0033 mmol), potassium carbonate (14 mg, 0.1 mmol) and water (0.1 mL). The resulting reaction mixture was degassed with nitrogen for 10 mm, then heated to 90C for 5h. Then the reaction mixture was diluted with ethyl acetate and washed with water. The organic phase was dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by SiC2 column chromatography (hexanes I EtOAcfrom 1:1 to 1:8) to give 6 mg (47%) of the product as a colorless oil.

Reference： [1]Patent: WO2018/13430,2018,A2 .Location in patent: Page/Page column 86

23
[ 886593-45-9 ]
6-bromo-3-[4-(propan-2-yloxy)phenyl]imidazo[1,2-a]pyridine [ No CAS ]
2-(4-{3-[4-(propan-2-yloxy)phenyl]imidazo[1,2-a]pyridin-6-yl}phenyl)propan-2-ol [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
52%	With [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II); potassium carbonate; In 1,2-dimethoxyethane; water; at 90℃; for 5h;Inert atmosphere;	To a solution of 6-bromo-3-[4-(propan-2-yloxy)phenyl]imidazo[1 ,2-a]pyridine (20 mg, 0.O6mmol) in1 ,2-dimethoxyethane (0.8 mL) were added <strong>[886593-45-9][4-(2-hydroxypropan-2-yl)phenyl]boronic acid</strong> (22 mg,0.1 2mmol), [1,1 ?-bis(diphenylphosphino)ferrocene]palladium(ll) dichloride (4.4 mg, 0.OO6mmol),potassium carbonate (25 mg, 0.18 mmol) and water (0.2 mL). The resulting reaction mixture wasdegassed with nitrogen for 10 mm, then heated to 90C for 5 h. Then the reaction mixture was dilutedwith ethyl acetate and washed with water. The organic phase was dried over Na2504, filtered, andconcentrated in vacuo. The residue was purified by SiC2 column chromatography (hexanes I EtCAc from 1:1 to 1:10, then pure EtCAc) to give 12 mg (52%) of the product as a colorless oil.1H NMR (300 MHz, CDCI3) O8.42 (5, 1H), 7.82 (d, 1H), 7.66 (5, 1H), 7.59 (d, 2H), 7.48-7.51 (m, 3H), 7.46 (d, 2H), 7.05 (d, 2H), 4.62-4.64 (m, 1H), 2.20-2.45 (brs, 1H), 1.62 (5, 6H), 1.40 (d, 6H). LCIMS m/z: 387.27(M+H).

Reference： [1]Patent: WO2018/13430,2018,A2 .Location in patent: Page/Page column 90

24
[ 886593-45-9 ]
C₁₇H₁₇IN₆O₂ [ No CAS ]
5-(4-(2-hydroxypropan-2-yl)phenyl)-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
28.8%	With (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; sodium carbonate; In 1,4-dioxane; water; at 80℃;Inert atmosphere;	[0411] A mixture of Example 52a (50 mg, 0.11 mmol), Example 52b (23.35 mg, 0.13 mmol) in 1,4- dioxane/H20 (5mL, 10: 1) was added Pd(dppf)2Cl2 (5 mg, 0.0068 mmol) and Na2C03(34.26 mg, 0.33 mmol). Then the mixture was degassed by bubbling argon through the solution for 10 min using a syringe needle. After that, the mixture was heated to 80C and stirred for overnight at 80C. The mixture was concentrated under reduced pressure to give the residue. The residue was purified by Prep-HPLC (by Ultimate XB-C18, 50 x 250 mm, 10 mupiiota, speed: 80 mL/min, eluent: H20/CH3CN = from 80/20 to 20/80 over 50 min) to give product (14.7 mg, Yield 28.8%) as a white solid.LCMS [M+l]+ = 473.0 [0412] 1H NMR (400 MHz, DMSO-d6) delta 12.73 (s, 1H), 8.89 (s, 1H), 8.75 (d, J= 2.8 Hz, 1H), 8.60 (d, J = 2.8 Hz, 1H), 8.38 (d, J= 8.3 Hz, 1H), 8.03 (t, J= 8.0 Hz, 1H), 7.82 (d, J= 7.1Hz, 1H), 7.57 (dd, J = 8.7, 12.8 Hz,4H), 5.30 (m, 1H), 5.06 (s, 1H), 3.71 (s, 3H), 1.53 (d, J= 6.7 Hz, 6H), 1.44 (s, 6H).

Reference： [1]Patent: WO2018/151830,2018,A1 .Location in patent: Paragraph 0411-0412

25
[ 6332-56-5 ]
[ 886593-45-9 ]
C₁₄H₁₄N₂O₄ [ No CAS ]

Reference： [1]ACS Medicinal Chemistry Letters,2019,vol. 10,p. 383 - 388

26
[ 886593-45-9 ]
C₁₄H₁₆N₂O₂ [ No CAS ]

Reference： [1]ACS Medicinal Chemistry Letters,2019,vol. 10,p. 383 - 388

27
[ 886593-45-9 ]
C₃₃H₃₅N₇O₄ [ No CAS ]

Reference： [1]ACS Medicinal Chemistry Letters,2019,vol. 10,p. 383 - 388

28
[ 886593-45-9 ]
N-cyclopropyl-6-((1-(4-(2-hydroxypropan-2-yl)phenyl)-2-oxo-1,2-dihydropyridin-3-yl)amino)-8-(methylamino)imidazo[1,2-b]pyridazine-3-carboxamide [ No CAS ]

Reference： [1]ACS Medicinal Chemistry Letters,2019,vol. 10,p. 383 - 388

29
[ 886593-45-9 ]
1-(3-bromo-5-chlorophenyl)cyclobutanecarboximidamide hydrochloride [ No CAS ]
1-(5-chloro-4′-(2-hydroxypropan-2-yl)-[1,1′-biphenyl]-3-yl)cyclobutanecarboximidamide [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2019,vol. 62,p. 4120 - 4130

30
[ 886593-45-9 ]
6-(4-(4-bromophenyl)piperazin-1-yl)-9-((3aR,4R,6R,6aR)-6-(((tert-butyldimethylsilyl)oxy)methyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-9H-purine [ No CAS ]
C₃₈H₅₂N₆O₅Si [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2019,vol. 62,p. 4483 - 4499

31
[ 886593-45-9 ]
[ 64978-35-4 ]
1-(4-(2-hydroxypropan-2-yl)phenyl)-3,4,6-tri-O-benzyl-D-glucal [ No CAS ]

Reference： [1]Journal of the American Chemical Society,2019

Same Skeleton Products

Related Products

Historical Records

Related Functional Groups of
[ 886593-45-9 ]

Organoboron

[ 1036760-03-8 ]

(3-(1-Hydroxyethyl)phenyl)boronic acid

Similarity: 0.96

[ 518336-20-4 ]

(4-(1-Hydroxyethyl)phenyl)boronic acid

Similarity: 0.96

[ 59016-93-2 ]

4-(Hydroxymethyl)benzeneboronic acid

Similarity: 0.86

[ 87199-15-3 ]

3-(Hydroxymethyl)phenylboronic acid

Similarity: 0.84

[ 16152-51-5 ]

4-Isopropylphenylboronic acid

Similarity: 0.84

Aryls

[ 1036760-03-8 ]

(3-(1-Hydroxyethyl)phenyl)boronic acid

Similarity: 0.96

[ 518336-20-4 ]

(4-(1-Hydroxyethyl)phenyl)boronic acid

Similarity: 0.96

[ 59016-93-2 ]

4-(Hydroxymethyl)benzeneboronic acid

Similarity: 0.86

[ 87199-15-3 ]

3-(Hydroxymethyl)phenylboronic acid

Similarity: 0.84

[ 16152-51-5 ]

4-Isopropylphenylboronic acid

Similarity: 0.84

Alcohols

[ 1036760-03-8 ]

(3-(1-Hydroxyethyl)phenyl)boronic acid

Similarity: 0.96

[ 518336-20-4 ]

(4-(1-Hydroxyethyl)phenyl)boronic acid

Similarity: 0.96

[ 59016-93-2 ]

4-(Hydroxymethyl)benzeneboronic acid

Similarity: 0.86

[ 87199-15-3 ]

3-(Hydroxymethyl)phenylboronic acid

Similarity: 0.84

[ 137756-89-9 ]

(4-(2-Hydroxyethyl)phenyl)boronic acid

Similarity: 0.82

Ghs Precautionary Statements

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Purity	Size	Price	VIP Price	USA Stock *0-1 Day	Global Stock *5-7 Days	Quantity
{[ item.p_purity ]}	{[ item.pr_size ]}	{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]}	{[ getRatePrice(item.pr_usd, 1,1) ]}	Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]}	{[ item.pr_usastock ]}	Inquiry -	{[ item.pr_chinastock ]}	Inquiry -

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

[ CAS No. 886593-45-9 ] {[proInfo.proName]}

Quality Control of [ 886593-45-9 ]

Related Doc. of [ 886593-45-9 ]

Product Details of [ 886593-45-9 ]

Calculated chemistry of [ 886593-45-9 ]

Physicochemical Properties

Pharmacokinetics

Lipophilicity

Druglikeness

Water Solubility

Medicinal Chemistry

Safety of [ 886593-45-9 ]

Application In Synthesis of [ 886593-45-9 ]

[ 886593-45-9 ] Synthesis Path-Upstream 1~2

[ 886593-45-9 ] Synthesis Path-Downstream 1~31

Related Functional Groups of [ 886593-45-9 ]

Organoboron

Aryls

Alcohols

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Related Functional Groups of
[ 886593-45-9 ]